DeDora Capital Inc. Has $703,000 Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

DeDora Capital Inc. lowered its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 29.3% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,209 shares of the medical research company’s stock after selling 500 shares during the quarter. DeDora Capital Inc.’s holdings in Thermo Fisher Scientific were worth $703,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Fifth Third Wealth Advisors LLC raised its holdings in Thermo Fisher Scientific by 24.3% during the first quarter. Fifth Third Wealth Advisors LLC now owns 2,397 shares of the medical research company’s stock valued at $1,393,000 after buying an additional 469 shares in the last quarter. Dohj LLC bought a new position in shares of Thermo Fisher Scientific in the 1st quarter valued at approximately $600,000. Lockerman Financial Group Inc. bought a new stake in Thermo Fisher Scientific during the first quarter worth approximately $217,000. Thrive Wealth Management LLC raised its position in shares of Thermo Fisher Scientific by 12.2% in the first quarter. Thrive Wealth Management LLC now owns 3,119 shares of the medical research company’s stock valued at $1,813,000 after purchasing an additional 339 shares during the period. Finally, Procyon Advisors LLC lifted its position in Thermo Fisher Scientific by 22.1% during the 1st quarter. Procyon Advisors LLC now owns 12,146 shares of the medical research company’s stock worth $7,059,000 after acquiring an additional 2,196 shares during the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $572.41, for a total transaction of $5,724,100.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares in the company, valued at $70,873,516.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $572.41, for a total transaction of $5,724,100.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares in the company, valued at $70,873,516.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Michael A. Boxer sold 14,566 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the transaction, the senior vice president now owns 12,901 shares of the company’s stock, valued at approximately $7,250,362. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 62,277 shares of company stock valued at $35,373,364. 0.34% of the stock is owned by insiders.

Thermo Fisher Scientific Trading Up 0.2 %

TMO stock traded up $1.13 during midday trading on Friday, hitting $572.38. 1,749,670 shares of the company’s stock were exchanged, compared to its average volume of 1,409,187. The stock’s fifty day moving average price is $575.39 and its 200-day moving average price is $532.82. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.33 and a current ratio of 1.70. The company has a market cap of $218.48 billion, a PE ratio of 36.71, a price-to-earnings-growth ratio of 2.37 and a beta of 0.80. Thermo Fisher Scientific Inc. has a one year low of $415.60 and a one year high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, topping the consensus estimate of $4.70 by $0.41. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. The firm had revenue of $10.35 billion for the quarter, compared to analyst estimates of $10.14 billion. Research analysts predict that Thermo Fisher Scientific Inc. will post 21.64 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Friday, March 15th were given a $0.39 dividend. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.27%. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s payout ratio is currently 10.01%.

Analyst Ratings Changes

TMO has been the topic of a number of recent research reports. HSBC lifted their target price on Thermo Fisher Scientific from $660.00 to $670.00 and gave the stock a “buy” rating in a research report on Tuesday. Royal Bank of Canada raised their price target on Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an “outperform” rating in a report on Thursday, February 1st. Sanford C. Bernstein reiterated a “market perform” rating on shares of Thermo Fisher Scientific in a research report on Monday, January 8th. Barclays increased their price objective on Thermo Fisher Scientific from $590.00 to $615.00 and gave the company an “equal weight” rating in a research report on Thursday, April 25th. Finally, The Goldman Sachs Group increased their price objective on Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a research report on Wednesday, April 10th. Five investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $607.35.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.